Why the study?
Is concomitant transcatheter aortic valve-in-valve and tricuspid valve-in-ring implantation feasible in high-risk patients?
Is concomitant transcatheter aortic valve-in-valve and tricuspid valve-in-ring implantation feasible in high-risk patients?
Concomitant transcatheter aortic valve-in-valve and tricuspid valve-in-ring procedures are feasible in high-risk patients requiring redo surgery.
Hypothesis-generating for concomitant transcatheter redo valve procedures; larger studies needed before clinical adoption.
Background Transcatheter heart valve (THV) therapies have shown to be an alternative to surgical valve replacement, especially in high-risk patients requiring redo surgery. However, reports of transcatheter-based interventions in tricuspid valve position are scarce. Case Description Here, we report a case of successful concomitant transcatheter aortic valve-in-valve (ViV) and tricuspid valve-in-ring (ViR) procedures using a 23-mm CoreValve Evolut R THV (Medtronic, Inc., Minneapolis, Minnesota, United States) in aortic position and a 29-mm SAPIEN3 (Edwards Lifesciences, Inc., Irvine, California, United States) THV in tricuspid position. Conclusion This case demonstrates feasibility of concomitant transcatheter aortic ViV and tricuspid ViR procedures.
No takes yet. Share an insight, caveat, or question.
Reichart et al. (2017) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: